Ocular Therapeutix shifts SOL-R endpoint timing, keeps AXPAXLI NDA on track for Q4 2026Nov 9Regulatory decisionImmunocore LtdKaryopharm Therapeutics IncUpdated
Ocular Therapeutix chief strategy officer resigns to lead private companyOct 16PeopleOcular Therapeutix, Inc.
Ocular Therapeutix targets Q4 2026 AXPAXLI NDA filing for wet AMD after FDA meetingAug 3Quarterly updateOcular Therapeutix, Inc.